1Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India, 110054
2Postgraduate Institute of Medical Education and Research, Department of Nuclear Medicine, Chandigarh, India 160012
3Department of Chemistry, Babasaheb Bhimrao Ambedkar University, (A Central University), Vidya Vihar, Raebareli Road, Lucknow - 226025
*Corresponding author:Raunak Varshney, Division of Cyclotron and Radiopharmaceutical Sciences, Delhi, India, 110054, Email: raunak_varshney@yahoo.com, raunak@inmas.drdo.in
Submission: August 25, 2020 Published: October 09, 2020
ISSN:2637-773XVolume5 Issue3
Peptides-coupled imaging agents are emerging as a new tool for early diagnosis with low adverse effects. Peptide-receptor based radiolabeled complex with good affinity to target specific receptors in cancers are required for imaging and quantification. Receptor mediated targeting of tumors for diagnosis, therapy or both is an encouraging approach and has increased remarkably over past 10-15 years. The attainment of these approaches related to selection of specific receptor for certain cancer type and their binding to the specific ligand. Receptor targeting radiopharmaceuticals are easy to synthesize and being small molecules, they exhibit excellent permeability, low immunogenicity, high specificity and minimum side effects. Gastrin-releasing three mammalian bombesin peptide receptors have shown great potential for cancer targeting because of their overexpression in various human malignancies. This review discusses the recent advances of bombesin receptors as potential targets for diagnosis using radiolabel bombesin analogues in prostate, lung, and breast cancer.
Keywords: Bombesin; Cancer; Gastrin-releasing peptide; Prostate cancer; Breast cancer; Lung cancer
Abbreviations: BN: Bombesin; CT:Computed Tomography; 64Cu: Copper-64; 18F: Fluorine-18; GRPR: Gastrin-Releasing Peptide Receptor; 68Ga: Gallium-68;HER 2: Human Epidermal Growth Factor Receptor Type 2; 111In: Indium-111; 177Lu: Lutetium-177; NMB:Neuromedin B Receptor; PET: Positron Emission Tomography; PSMA: Prostate-Specific Membrane Antigen; SPECT: Single Photon Emission Computed Tomography; SUV Max: Maximum Standardized Uptake Value; 99mTc: Technetium-99m; 90Y: Yttrium-90